| |
 |
 |

William
Wedemeyer, Ph.D.
Assistant Professor
Department of Biochemistry and Molecular Biology
Ph.D.,
1998, Cornell University
Postdoctoral Fellow, 1998-2001, Cornell
University
Postdoctoral Fellow, 2001-2003,
University of Washington, Seattle
Address:
Department of Microbiology and Molecular Genetics
4226 Biomedical Physical Sciences
Michigan State University
East Lansing, MI 48824
Email: proteins@msu.edu
Telephone: (517) 355-1604 |
|
|
| |
Research
The
Wedemeyer lab combines computational and experimental
methods to answer important biological questions about
protein structure. Our principal focus is gp120 (the
envelope protein of HIV) but we are also pursuing basic
research about the physics of protein folding using
peptides and small proteins. Our software is protected
by the GNU Public License.
Conformational
Changes in gp120 During HIV-1 Cell Entry
HIV is perhaps the most critical public health problem
of our time, with roughly 40 million people infected
and roughly 10,000 deaths per day. The HIV envelope
protein, gp120, is the principal target for vaccines
and antibody neutralization, being the sole exposed
viral protein. However, gp120-based vaccines have not
been successful and relatively few anti-gp120 antibodies
are effective at neutralizing the virus; of these few
antibodies, none are effective against all forms of
the virus.
We hypothesize that gp120 avoids neutralization
by cloaking the structures needed for infection until
the moment of infection. gp120 undergoes at least two
major conformational changes during viral entry, the
first upon binding to CD4 (its receptor on the target
cell) and the second upon binding to a cellular chemokine
receptor (either CCR5 or CXCR4). These conformational
changes in gp120 may produce the structures needed for
infection, either (1) by uncovering pre-formed but buried
structures or (2) by folding those structures from a
disordered or differently folded conformation. Unfortunately,
these conformational changes are poorly understood,
since gp120 is difficult to crystallize and too large
(approx. 477 residues) for traditional NMR.
We
are tackling this problem by combining de novo protein-structure
prediction methods with medium-resolution structural
probes, including 19F NMR, fluorescence, chemical modification,
and proteolysis. Our gp120 comes from a primary isolate
of clade A2 HIV-1, and has been cloned and expressed
in mammalian and insect expression systems. Virological
experiments are being carried out in parallel by our
collaborator, Mary Poss.
Computational
Protein Structure Prediction/Design
The methods of computational protein structure prediction
have matured in recent years, so that the structure
of individual domains can be predicted de novo (i.e.,
from the amino-acid sequence alone) within 3-5 Å
CA rmsd. Nevertheless, these methods are prone to fail
if the domain is unusually large (>150 residues),
has poorly predicted secondary structure, or has a high
fraction of long-range contacts. Moreover, there are
no reliable methods for refining approximately correct
structures (e.g., 5 Å CA rmsd to native) to higher
resolution (e.g., 3 Å CA rmsd). We are developing
new sampling methods and force-fields to overcome these
obstacles.
Experimental Studies of Protein/Peptide
Electrostatics
Successful protein prediction and design requires accurate
energy functions for scoring trial conformations. Unfortunately,
the electrostatic component of present-day energy functions
seems to be inaccurate; this is especially problematic,
since the electrostatic component is long-ranged. We
are studying the electrostatics of peptides and proteins
experimentally in an effort to improve these potential
functions.
|
|